Funding for Phase 1 & 2

In February 2018, an $8 million-dollar grant from the National Centre for Research and Development in Poland for the development of WPD101 that would include Phase I clinical studies in GBM tumors.




WPD101 has not been submitted for FDA or EMA approval so far.


Additional Indications

Wake Forest Baptist Medical Center
Recognized, fully integrated academic medical center and health system located in Winston-Salem, North Carolina, USA.

North Carolina Baptist Hospital
Operates in patient hospitals, community health centers, health maintenance organization, primary care centers and teaching hospitals as a subsidiary of Wake Forest Baptist Medical Center.

WPD Pharmaceuticals
Co-development partner.


Preclinical Development

WPD101 is currently in preclinical development and its consistent anticancer properties are demonstrated and validated in dogs with spontaneous GBM closely resembling GBM in human patients. Overall, results of these studies indicate the significant potential of WPD101 demonstrating the same effective treatment of GBM in humans. Phase I of clinical trial is expected to begin in 2020.


Subsequent Studies

Primary focus on GBM and subsequently on other cancers with similarly high overexpression of IL-13RA2 and EphA2 receptors (for example uveal melanoma).


Additional Indications

In addition to GBM, it is known that uveal melanoma cancer cells also express a high level of IL-13RA2 receptors. WPD Pharmaceuticals is going to develop WPD101 therapy in a uveal melanoma model, the localization of which allows local drug administration.